Title: Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal

adenocarcinoma

Authors: Riley J. Arseneau[1,2], Jorge P. Mejia[2,3], Sarah Nersesian[2,3,&], Stacey N. Lee[3], Carley Bekkers[4],

Thomas Samson[5], Daniel Gaston[1,2,4], Boris L. Gala-Lopez[1,2,3,6], Ravi Ramjeesingh[1,2,7], Thomas

Arnason[1,4], Jeanette E. Boudreau[1,2,3]

Affiliations:

[1]Department of Pathology, Dalhousie University, Halifax, NS, Canada

[2]Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada

[3]Department of Microbiology & Immunology, Dalhousie University, Halifax NS, Canada

[4]Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority, Halifax, NS,

Canada

[5]Faculty of Medicine, Dalhousie University, Halifax, NS, Canada

[6]Department of Surgery, Dalhousie University, Halifax, NS, Canada

[7]Division of Medical Oncology, Department of Medicine, Nova Scotia Health, Dalhousie University,

Halifax, NS, Canada

[&]Current affiliation: Ottawa Hospital Research Institute, Ottawa, ON, Canada

* Address for correspondence:

Dr. Jeanette E. Boudreau

Jeanette.boudreau@dal.ca

5850 College Street, Room 15-F2, Halifax, NS, Canada, B3H 4R2

Running title: T cells predict longer survival in PDAC

Keywords: T cells, PDAC, Spatial Biology, pancreatic cancer, lymphocytes

Conflicts of interest: The authors declare they have no conflicts of interest

Word count: 5240

Number of Figures: 5

Number of tables: 1

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, and

has limited options for treatment. Low immune infiltration, desmoplastic stroma, and poor tumour

immunogenicity are all expected to contribute to PDAC's rapid progression and limited response to

existing immunotherapies. PDAC tumours are mosaics of different sub-tumour microenvironments,

including some that do contain immune cells. We hypothesized that increasing frequency of

lymphocyte:tumour interactions would correlate with lengthened survival for patients with PDAC.

Methods: Using multiplex immunofluorescence, digital pathology, and computational analyses, we

profiled the spatial distribution, co-localization, and neighbourhood architecture of immune cells in

tumours from 73 patients with PDAC.

Results: Higher densities of CD3+CD8– (CD4+) T cells were associated with improved five-year

overall survival, particularly when enriched at the tumour-stroma boundary (i.e. peritumoural).

CD3+CD8- T cells, CD8+ T cells (CD3+CD8+), and B cells (CD20+) frequently co-infiltrated and co-

localized, forming distinct immune neighbourhoods indicative of organized adaptive immunity. We

defined three common immune neighbourhoods within PDAC (1) Macrophage-dominant; (2) T cell

dominant; and (3) Disorganized. With greater tumour and peri-tumoural area represented by the T

cell dominant neighbourhood, overall survival was increased. The other neighbourhoods were not

significantly associated with outcomes.

Conclusion: Immune cells self-assemble in predictable patterns in PDAC. The presence of T cell

dominant neighbourhoods, which we interpret as supporting ongoing immune activation, best

predict lengthened survival. Spatially organized immune interactions may serve as prognostic

indicators and inform future studies for immunotherapies in PDAC.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) remains fatal in greater than 80% of patients, with few options for effective treatment.[1] immunotherapies like immune checkpoint blockade or chimeric antigen receptor (CAR)-T cells have transformed treatment of other cancers, such as melanoma and leukemia,[2,3] but PDAC remains refractory to existing immunotherapeutic interventions.[4] PDAC is often classified as an immunologically "cold" tumour, with a tumour microenvironment (TME) marked by dense desmoplasia, poor immune cell infiltration, a low mutational burden/neoantigen availability, and a high density of immunosuppressive cells such as M2 macrophages and regulatory T cells (Tregs).[4,5] However, recent immunohistochemical assessments have revealed that PDAC is heterogenous both within and between patients, a product of its "sub-TMEs".[6] Among these are immune-enriched regions; this implies that immunity (and immunotherapy) remain possible in PDAC.[6–10] In agreement, recent clinical investigations have demonstrated that neoantigen-targeting personalized vaccines can drive effective cytotoxic T cell anti-tumour immunity in patients with PDAC[11,12]. There is thus a need to better understand the immune microenvironment in PDAC: the composition of tumour and immune cells and their spatial interactions may provide prognostic insights that ultimately inform more precise care and future immunotherapies.

Immune-mediated tumour killing requires contact between tumour cells and cytotoxic immune cells or their products (i.e. antibodies). Activation for anti-tumour immunity requires a co-ordinated effort between immune cells that requires contact between antigen presenting cells, helper T cells and effector lymphocytes. Increasingly, the spatial context of immune-tumour interactions is being interrogated to better understand putative cell-cell communication, activation, and priming—and predicting patient outcomes.[13–17] For example, tertiary lymphoid structures that localize T cells, B cells, and antigen presenting cells enable anticancer immunity.[18] We recently demonstrated that clusters of macrophages, T cells, and natural killer (NK) cells infiltrating the

tumour epithelial regions predicted the longest progression free survival in patients with high grade

serous carcinoma of the ovary.[16] The co-localization of immune cells with complementary functions

to collaboratively drive anticancer immunity best associated with patient survival, perhaps

underscoring a requirement for immune cell co-operation in tumour microenvironments.[16] Whether

a similar co-operation of immunity occurs in PDAC has not been investigated.

In this study, we used multiplex immunofluorescence (mIF) to assess the spatial

distribution, co-localization, and neighbourhood formation of macrophages, T cells, NK cells, and B

cells in 73 surgically-resected PDAC tumours. We designed a novel approach to segregate tumours

into epithelial, peri-tumoural and stromal regions, because unlike most solid tumours where there

is a clear delineation of tumour epithelium from its surrounding stroma, PDAC initiates in ducts and

metastasizes via small satellite tumour clusters.[19,20] We observed that enrichment of CD3+CD8– T

cells (likely CD4+ helper T cells) was associated with longer five-year overall survival (OS),

particularly when they are at the tumour-stroma (peritumoural) interface. The survival benefit was

further enhanced in patients with CD3+CD8- T cells in the stroma co-occurring with CD3+CD8+

(cytotoxic) T cells in the tumour epithelium, consistent with CD8+ T cell activation supported by

regional support from helper T cells. Unsupervised clustering revealed three patterns of immune cell

co-localization ("neighbourhoods"); one among them, containing CD3+CD8– T cells, CD3+CD8+ T

cells, and B cells, was associated with the best outcomes for patients. This neighbourhood may

represent regions of organized adaptive immunity and their presence in PDAC could therefore

represent a productive anti-cancer response. Hence, these T cell-enriched areas may inform patient

prognosis or precision medicine. While functional assessments will be required to determine the

specific anti-cancer activities and driving features of these neighbourhoods, their presence

underscores optimism for future, novel immunotherapies to support cytotoxic immunity in PDAC.

Methods

Patient samples

Samples were obtained from 76 patients with PDAC who underwent surgical resection from 2013 to 2024 at the Queen Elizabeth II Health Sciences Centre (Nova Scotia, CAN). This study was approved by the Nova Scotia Health institutional research ethics board (#1023467 & #1026628). Patients who received neoadjuvant therapy were excluded. Patient information is available in **Supplementary Table 1.**

Patient samples were formalin-fixed, paraffin-embedded (FFPE) and assembled into tissue microarrays (TMA). Each patient was represented by duplicate 3 mm cores selected from regions containing >30% tumour cells, as identified by board-certified pathologist (TA).

Multiplex immunofluorescence

Opal mIF (Akoya Biotechnology, Marlborough, USA) was performed as previously described.[16] Briefly, 4 µm sections were prepared from the TMAs, deparaffinized in Xylene (Sigma-Aldrich) (3 x 10 min) and rehydrated by incubating with decreasing concentrations of ethanol for 10 min each (100%, 100%, 95%, 70%). The slides were then fixed in 10% neutral buffered formalin (VWR) for 20 min.

The slides underwent serial cycles of antigen retrieval, primary staining, and tyramide signal amplification to add each antibody and fluorophore one by one. For antigen retrieval, slides were microwaved in Tris-EDTA buffer (pH9) at 1000W for 2 min, then 200W for 15 min. The slides were cooled on ice for 10 min and rinsed in deionized water and Tris-buffered saline with Tween-20 (TBS-T). Slides were thereafter blocked in 1x antibody diluent/block (Akoya Biosciences) for 10 min, the excess block was removed, and the slides were stained with diluted primary antibody for 45 min. After TBS-T rinsing, slides were incubated in secondary anti-mouse plus rabbit antibodies conjugated to horseradish peroxidase (HRP) for 10 min. Signal amplification was completed via HRP-

driven tyramide activation and fluorophore deposition and tissue binding (Opal 6-Plex Manual

Detection Kit, and Opal 480 Reagent Pack (Akoya Biosciences)). Opal 780 staining (Opal 780 Reagent

Pack, Akoya Biosciences) required use of digoxygenin labeling prior to tyramide signal amplification

(10 min, TSA Plus DIG, Akoya Biosciences). The slides were rinsed in TBS-T and subsequently

incubated in the corresponding Opal fluorophore diluted in Opal amplification diluent for 10 min

(Opal 480, 520, 540, 570, 620, 650, and 690 fluorophores) or 1h (Opal 780). After the final staining

step, slides were counterstained with Spectral DAPI (ThermoFisher) for 10 min, rinsed, and mounted

in Mowiol-based mounting medium (Mowiol, glycerol, deionized H_2O, TrisHCl (pH 8.5); Sigma-

Aldrich)). Antibodies, Opal fluorophores with which they were used, and staining order are shown in

Table 1.

Antibody staining was validated using FFPE tonsil tissue and cell pellets of purified T and NK

cells. T and NK cells were isolated from primary peripheral blood mononuclear cells (Canadian

Blood Services, Dalhousie REB 2016-3842), centrifuged at 300 x g for 5 min, fixed in 10% neutral

buffered formalin, and processed for paraffin embedding. All staining patterns were confirmed by a

board-certified pathologist (TA). Representative images from one case and the segmentation

pipeline are shown in **Figure 1A**.

Table 1. Staining panel and order for mIF				
Phenotype	Marker	Clone	Dilution	Fluorophore
NK cells	CD57	NK1	1/50	650
M2 Macrophage	CD163	ERP19518	1/200	540
Macrophage/monocyte	CD68	SP251	1/100	690
Epithelial Cell	PanCk	AE1/AE3	1/100	520
Pan T cell	CD3	LN10	1/50	480
NK cells/monocyte	CD16a	SP175	1/50	620
Cytotoxic T cell	CD8	C8/144	1x	480
B cell	CD20	L26	1/25	780
DAPI (nuclear stain)	DAPI	N/A	15 µM	N/A

Figure 1. Quantitative image and neighbourhood analysis workflows. A) Fluorescent microscopy image using 9-colour mIF. Markers used include DAPI (blue), CD3 (orange), CD8 (cyan), CD57 (white), CD16a (red), CD68 (magenta), CD163 (yellow), CD20 (pink), and panCK (green). Representative pathology views for each marker are shown. **B)** Quantitative pathology workflow with tissue and cell segmentation based on PanCK and DAPI staining, respectively. **C)** x,y coordinates were used to reconstruct maps of tumours *in silico*. Cell groups were defined as at least five cells within a 30 µm

147 radius and k-means clustering identified cell neighbourhoods. Davies-Bouldin indexing was used to
148 define the ideal number of neighbourhoods, whose cellular compositions are reported as bar
149 graphs.
150
Imaging was completed using a Mantra Quantitative Pathology workstation equipped with

after-market Opal 480 and Opal 780 filter cubes. Images were acquired at 20x magnification, with

wavelength intervals spanning emission peaks between 420 nm and 780 nm to capture all Opal

fluorophores. Up to 15 images per core were captured, with multispectral analysis performed in

InForm Tissue Finder Software (Version 2.4.8). Spectral reference libraries, generated from

monoplex stains for each fluorophore, were used for spectral unmixing to distinguish fluorophore

signals and control for autofluorescence. Regions of benign panCK+ staining were omitted and

regions of tumour epithelium were confirmed by a board-certified pathologist (TA).

Using machine learning algorithms, tissue segmentation was performed on spectrally

unmixed images to distinguish epithelial and stromal regions (off-core regions were omitted and

could be distinguished from stroma by lack of DAPI staining and tissue autofluorescence). Nuclear

segmentation (DAPI) followed, and cell phenotypes were assigned by antibody staining. Phenotype

maps with x,y cell coordinates classified each cell with a unique cell ID **(Figure 1B)**. Cell types were

classified based on antibody expression profiles: panCK+ as epithelial cells (regardless of other

antibody binding), PanCK-CD68+ as macrophages (CD163+/– , CD16a+/–), PanCK–CD68–CD3+ as T

cells (CD8+/–, CD16a+/–, CD57+/–), PanCK–CD3–CD68–CD57+ as NK cells (CD16a+/–), PanCK–

CD3–CD68–CD57–CD16a+ as CD16a+ cells, and panCK–CD3–CD68–CD20+ as B cells. Cells

staining with DAPI only were categorized as "Other". Antibody binding patterns, cell surface staining,

cell segmentation, and phenotyping were validated by a board-certified pathologist (TA).

Quality control involved visual assessment of every image and excluding images with poor

tissue quality or non-specific staining. All quality control was performed blinded to clinical outcome

data. Of the 76 patients intended for study, images from 73 patients passed staining and quality

control and were included in the final analysis.

Cell densities and spatial analyses

Cell densities

Cell identities and x,y coordinates were exported from InForm. Cell densities were calculated in

RStudio (Boston, MA USA, version 2022.12.0) using the dplyr package.[21] For each patient, total

counts of each cell type between duplicate cores within the epithelial and stromal compartments

were summed and divided by the corresponding tissue area, resulting in region-normalized average

densities per patient (cells per mm^2). For cell-, neighbourhood, and region-level analyses, we

calculated the density (cells/mm^2) of each immune cell subset (or neighbourhood) per patient.

Density distribution curves were generated using the density () function in base R, and the division

into "high" and "low" densities was defined by the maxima, minima, or inflection point closest to the

median of each distribution.

T cell infiltration score

We generated a T cell infiltration score, following an approach like that used in Immunocore algorithm

used in colorectal cancer.[22,23] The T cell infiltration score ranged from 0 to 6 and was calculated by

summing binary high/low infiltration designations of CD3+CD8+ and CD3+CD8– T cells across the

epithelial and stroma compartments. Informed by compartment specific role of each subset,[24–27] we

assigned a greater weight to the subset most biologically relevant in each region. Patients received

two points for high CD3+CD8– T cell infiltration in the stroma and one point for high CD3+CD8+

infiltration in the stroma. Conversely, high CD3+CD8+ infiltration in the epithelium contributed two

points, while CD3+CD8– in the epithelium contributed one point. Patients were stratified into three

groups based on total score: low (0 points), intermediate (1-3 points), and high (4-6 points).

Neighbourhood analysis

Our spatial biology workflow was adapted from previously published methods[15,16] and conducted in

Python (Version 3.9.18). X,y coordinates of each cell were used to reconstruct phenotype maps of

tumours, and each cell was defined as an index. Cell IDs with their x,y coordinates and assigned

phenotypes were grouped by image and patient using Pandas[28] (for data organization and

manipulation) and NumPy[29] (for numerical operations). Using the BallTree module from scikit-

learn[30], for each index cell, cells within a 30 μm radius were identified based on their x,y, coordinates

(nearest neighbour search), defining local "groups" **(Figure 1C)**. To identify patterns of immune cell

co-localization, which we termed "neighbourhoods", three images from each patient were randomly

selected and combined to create a training set. Using this set, K-means clustering through

MiniBatchKMeans algorithm (scikit-learn) was applied to the immune cell populations only, testing

between 2 and 10 potential neighbourhoods. The optimal number of neighbourhoods to represent

intra-tumour diversity was defined using Davies-Bouldin indexing (scikit-learn).[31]

All remaining images were classified using the trained model to assign each cell to a

neighbourhood. To ensure neighborhood definitions reflected immune cell organization (not tumour

or other cells), epithelial (PanCK+) and "Other" cells were excluded from the clustering and instead

assigned to distinct "PanCK" and "Other" neighborhoods. This approach preserved their spatial

position in the radius-based analysis while preventing them from influencing immune

neighbourhood structure. Consistency of neighbourhood classification was validated by calculating

cosine similarity (scikit-learn), which scored >0.99 between the initial training set and the

subsequent classified images. Figures were generated with matplotlib[32] and seaborn[33].

Tumour neighbourhood analysis

To define tumour regions as intratumoural, peritumoural, and stromal, cell clustering was performed

in Python using the DBSCAN[34] and SciPy[35] packages. Epithelial (panCK+) cells were first identified in

each sample, and DBSCAN clustering was performed on these cells using a 30 μm radius and a

minimum cluster size of five cells. Cells that did not meet this clustering criteria were excluded from

defining intratumoural regions. SciPy's ConvexHull class was used to define the smallest bounding

shape (convex hull) for each tumour cluster, with visual confirmation by a pathologist (TA). Based on

these boundaries, three regions were defined: (1) Intratumoural: the area formed by each tumour

site; (2) Peritumoural: a 30 μm perimeter surrounding each tumour site; or (3) Stromal: the area

outside the intratumoural and peritumoural regions. Cell counts for each region were aggregated by

radius for each patient, and patients were subsequently classified into high and low groups based on

the proportion of each immune phenotype within the defined regions, as defined above.

Statistical analysis

To define which clinical variables were associated with survival and therefore should be used as

covariates for downstream multivariate analysis, we performed univariate Cox proportional hazard

regressions using five-year OS as the dependent variable in RStudio. Independent variables were

tumour stage, tumour grade, age at diagnosis, sex, and lymph node invasion **(Supplemental Table**

S1). Among them, only increased regional lymph node metastasis was significantly associated with

shorter five-year OS ($p < 0.05$).

Univariate Kaplan-Meier and log-rank tests were conducted to assess differences in OS

between high and low groups of cell-, neighborhood-, and regional- analyses, and multivariate Cox

proportional hazards models were used to identify independent prognostic factors. Co-infiltration

between cellular phenotypes were assessed using Spearman's rank correlation in GraphPad Prism

(GraphPad Software, Boston, MA USA, version 10.2.3). Comparisons of immune cell infiltration

across clinically defined groups, including tumour stage (T1, T2, T3), tumour grade (1, 2, 3), age (<65,

≥65), sex (male vs female), and regional lymph node metastasis (N0, N1, N2), were conducted using

two-tailed Mann-Whiteney U tests in GraphPad Prism, with corrections for false discovery to account

for multiple comparisons. Statistical significance was defined as an alpha of 0.05 for all analyses.

Results

Patient characteristics

Using Opal mIF, we evaluated tumours from a total of 73 patients with PDAC who underwent surgical resection between 2013 and 2024 at the QEII Health Sciences Centre. Forty-five percent of the cohort was female; 55% were male **(Supplemental Table 1)**. Most patients were >65 years old (59%, n=43), and categorized as stage II (33%) or stage III (62%). Moderately differentiated tumours were most common (63%, grade 2), followed by poorly differentiated (23%, grade 3), and well-differentiated tumours (14%, grade 1). Regional lymph node involvement was most commonly present: just 14% had no positive lymph nodes (N0), 60% of patients had 1-3 positive lymph nodes (N1), and 21% having ≥4 nodes (N2). Patients with N0 disease had a lower risk of death compared to N2 (HR: 0.16, 95% CI: 0.04-0.73, p<0.05). Since this was the only clinical variable associated with OS, it was the only one included in downstream multivariate analyses.

Immune architecture of PDAC microenvironment

The immune microenvironment of PDAC is immunosuppressive and spatially heterogenous, yet remains poorly characterized, with limited knowledge of how it reflects patient prognosis.[4,5] To characterize the immune landscape of PDAC, we quantified immune cell densities (cells/mm^2) in both the epithelial and stromal compartments using multiplex IHC and quantitative pathology **(Figure 1)**. Tumours displayed marked immune infiltration with inter- and intra-patient heterogeneity **(Figure 2A)**. Regardless of phenotype, immune cell densities were higher in the stroma than in the epithelial compartment, likely reflecting limited accessibility to the tumour **(Figure 2A)**. Among immune populations, the most abundant were CD16a+ M2-like macrophages (epithelium median: 11.3, min-max: 0-280.1; stroma median: 569.1, min-max: 45.2-4602.0) and CD3+CD8+ T cells (epithelium median: 10.6, min-max: 0-216.1; stroma median: 234.4, min-max: 24.9-1446.0),

reflecting substantial infiltration in both compartments **(Figure 2A, Supplemental Table 2).** To

reduce complexity and improve interpretability, populations with a median cohort total density of <1

cell/mm^2 were grouped into higher-level phenotypes based on shared marker expression

(Supplemental Table 2). Specifically, PanCK–CD68–CD3+CD8–CD57+ and PanCK–CD68–

CD3+CD8–CD16a+ subsets were amalgamated into a CD3+CD8– T cell group; PanCK–CD68–

CD3+CD8+CD57+ and PanCK–CD68–CD3+CD8+CD16a+ subsets were grouped as CD3+CD8+ T

cells; and PanCK–CD68–CD3-CD8–CD57+CD16a– and PanCK–CD68–CD3-CD57+CD16a+ subsets

were grouped as NK cells.

Figure 2. Immune cell frequencies and associations with survival. (A) Violin plots showing the densities of individual immune cell phenotypes within the stromal and epithelial compartments of PDAC cores. The table below indicates the marker expression profile for each phenotype, with black squares with "+" denoting marker positivity and colours representing aggregate cell phenotypes employed in downstream analysis. **(B)** Forest plots of hazard ratios from univariate Cox regressions comparing high vs low densities of each phenotype. Solid red boxes indicate phenotypes significant in both univariate and multivariate models; dotted red boxes denote phenotypes significant in univariate analysis only.

Increased T cell density is associated with greater overall survival.

Previous studies indicated that T cells, B cells, and macrophages, and their specific subsets inform good or bad prognosis in PDAC,[36–39] thus we sought to determine whether immune cell densities in PDAC tumour compartments correlated with OS. We used univariate and multivariate Cox regression analyses to compare 5-year OS in patients with immune cell densities categorized as high or low.

By univariate analysis, higher densities of epithelial CD16a+ cells were associated with an increased risk of death (HR: 2.4, 95% CI: 1.4–4.4, p<0.05), while higher densities of CD3+CD8– T cells in both the stroma and total tissue compartments were significantly associated with reduced risk of death (HR: 0.55, 95% CI: 0.31–0.97, p<0.05; HR: 0.42, 95% CI: 0.24–0.75, p<0.05, respectively) **(Figure 2B)**. These associations remained significant after adjusting for regional lymph node involvement by multivariate assessment (epithelial CD16a+: HR: 2.1, 95% CI: 1.1-3.9, p<0.05; stromal CD3+CD8-: HR: 0.47, 95% CI: 0.26-0.85, p<0.05); total CD3+CD8-: HR: 0.43, 95% CI: 0.24-0.80, p<0.05) **(Supplemental Table 3)**. Increased M1-like macrophage density was associated with decreased risk of death in univariate analysis (HR: 0.48, 95% CI: 0.26–0.89, p<0.05), but this association was lost in the multivariate model (HR: 0.55, 95% CI: 0.30-1.0. Thus, immune cell infiltration itself does not suggest improved prognosis: different subsets are variably prognostic and CD3+CD8– T cells may be a marker of improved OS in patients with PDAC.

Combined CD3+CD8– and CD3+CD8+ T cells infiltration is associated with improved OS

Immune cells function as a coordinated network. We next hypothesized that the association of

CD3+CD8- T cells with improved OS might reflect a role for these cells–which are likely helper T cells–

in supporting anti-tumour immune functions, including that of cytotoxic (CD3+CD8+ T cells). Indeed,

patients with high infiltration of both CD3+CD8- and CD3+CD8+ T cell subsets exhibit significantly

improved OS compared to those low for both (HR: 0.33, 95% CI: 0.12–0.88, p<0.05). While high

infiltration of either subset alone trended toward lengthened OS, neither reached statistical

significance (CD3+CD8– only: HR: 0.45, 95% CI: 0.17-1.2, p =0.14; CD3+CD8+ only: HR 0.65, 95% CI:

0.14-3.0, p=0.88) **(Figure 3A)**. Notably, high infiltration of CD3+CD8+ T cells alone was uncommon

(7% of patients) **(Figure 3B)**. These findings suggest that co-infiltration of helper and cytotoxic T cells

might enable local generation of antitumour immunity.

Figure 3. Combined CD3+CD8- and CD3+CD8+ T cell infiltration is associated with improved OS. (A) Forest plot showing hazard ratios and 95% confidence intervals from univariate Cox

regression comparing patients categorized as high for CD3+CD8+ only, CD3+CD8- only, both, or
neither, based on total cell density. **(B)** Pie chart representing the percentage of patients in each T
cell group. **(C)** Schematic of the T cell infiltration score. Created in BioRender. Arseneau, R. (2025)
https://BioRender.com/teuxamp **(D)** Forest plot showing hazard ratios and 95% confidence
intervals from univariate Cox regression comparing patients based on infiltration score (low,
intermediate, and high). Kaplan-Meier survival plot comparing the five-year OS among patients
stratified by infiltration score.
330

High T cell infiltration score is predictive of longer OS

CD8+ cytotoxic T cell killing is contact-dependent, but helper T cells can function from a distance.

To evaluate whether compartment-specific localization influences prognosis, we generated a T cell

score **(Figure 3C)**. High T cell infiltration scores were associated with reduced risk of death and

improved survival compared to low in both univariate and multivariate Cox regression models (HR:

0.39, 95% CI: 0.16-0.90, p<0.05) and Kaplan-Meier survival analysis (p<0.05) **(Figure 3D&E,**

Supplemental Table S3). Patients with intermediate T cell infiltration scores exhibited a trend

towards decreased risk of death and lengthened OS compared to those with low scores, though the

difference did not reach statistical significance (HR: 0.46, 95% CI: 0.20-1.0, p=0.066) **(Figure 3D&E)**.

These findings suggest that the localization of T cell subsets with respect to tumour cells impact

patient prognosis.

Higher peritumoral CD3+CD8– T cell density corresponds to decreased risk of death

PDAC tumours grow as cells around pancreatic ducts, dispersed between dense stroma throughout

the pancreas; this is different from other solid tumours where groups of cancerous cells

aggregate.[19,20] Dichotomizing tumour versus stroma, as with other tumours, might therefore

inadequately capture immune:tumour interactions in PDAC. To refine the assessment of spatial

immune localization and its association with survival, we applied DBSCAN-based spatial clustering

to segment tissue into intratumoural, peritumoural, and distal stromal regions and measure immune

cell localization within them **(Figure 4A).** This approach enabled a more granular evaluation of

immune cell positioning at the tumour-stroma interface.

Within the intratumoural region, higher proportions of NK cells were associated with

increased risk of death (HR: 2.6, 95% CI: 1.4-4.7, p<0.05) **(Figure 4B, Supplemental Table 3)**.

Similarly, increased NK cell infiltration in the peritumoural space was also associated with worse

survival (HR: 2.3, 95% CI: 1.2-4.2, p<0.05). In contrast, higher proportions of CD3+CD8-T cells in the

peritumoural region were significantly associated with reduced risk of death (HR: 0.55, 95% CI: 0.30-

0.99, p<0.05). Within the distal stroma, both CD3+CD8– and CD3+CD8+ T cells were associated with

improved OS (HR: 0.53, 95% CI: 0.29-0.94, p<0.05; HR: 0.53, 95% CI: 0.29-0.95, p<0.05). Taken

together, these findings suggest that T cell localization, particularly at the tumour-stroma interface,

is predictive of prognosis in PDAC.

Figure 4. Immune cell proximity to the tumour predicts survival. (A) Schematic of DBSCAN-based
clustering analysis. **(B)** Forest plots of hazard ratios from univariate Cox regressions comparing high

vs low proportions of each phenotype in each region. Solid red boxes indicate phenotypes significant
in both univariate and multivariate models; dotted red boxes denote phenotypes significant in
univariate analysis only.
367

T cells and B cells colocalize in PDAC

Although T cell infiltration is often assessed for its prognostic capacity, effective immunity requires

cooperation between immune cell subtypes. To determine whether additional cells might interact

with T cells in the tumour environment, we performed Spearman's correlation analysis on average

immune cell densities across patients. Positive correlations were observed between CD3+CD8– and

CD3+CD8+ T cells (R = 0.64, p<0.001), CD3+CD8– T cells and B cells (R = 0.71, p<0.001), and

CD3+CD8+ T cells and B cells (R = 0.52, p<0.001) **(Figure 5A)**. These findings suggest that crosstalk

may occur between lymphocytes, which may prompt formation of niches within the PDAC

microenvironment.

Figure 5. Co-infiltration and spatial organization of T cells and B cells is associated with
improved patient outcomes in PDAC. (A) Co-infiltration of total cell densities in PDAC tumours,

determined by Spearman's correlation. Colour intensity indicates the strength of correlation, and dot size reflects the statistical significance (p-value). **(B)** Cell type proportions comprising the three immune neighbourhoods identified via spatial clustering. **(C)** Proportional representation of each immune neighbourhood in each of the 73 tumours assessed **(D)** Representative spatial neighbourhood maps demonstrating each neighbourhood subtype: Macrophage (Mac) dominant, T cell dominant, and Disorganized. **(E)** Forest plots of hazard ratios and 95% confidence intervals from univariate Cox regressions comparing "high" vs "low" proportions of each neighbourhood in the intratumoural region. Solid red box indicates neighbourhood significant in both univariate and multivariate models.

We next applied radius-based nearest neighbor clustering to ascertain potential interactions between immune cell types. With these, we identified three patterns of immune cell colocalization, which we termed "neighbourhoods". The first was a *macrophage dominant* neighbourhood, composed primarily of CD16a+ M2-like macrophages, consistent with an immunosuppressive function **(Figure 5B).** The second was a *T cell dominant* neighbourhood, enriched for CD3+CD8– T cells, CD3+CD8+ T cells, and B cells, which may represent areas of organized adaptive immunity. The third was a *disorganized* neighbourhood, characterized by a heterogenous mix of infiltrating immune cells without a dominant cell type, suggestive of an unstructured (and perhaps inefficient) immune response.

The relative area represented by each neighbourhood varied between patients; however, in most tumours, the disorganized neighbourhood comprised the largest proportion of immune cells, followed by the macrophage dominant neighbourhood, and then the T cell dominant neighbourhood **(Figure 5C,D)**. The disorganized and macrophage dominant neighbourhoods were observed in all patients, while the T cell dominant neighbourhood was present in ~90% of cases. Representative examples of each neighbourhood pattern are shown in **Figure 5D**.

To evaluate whether immune neighbourhoods were associated with patient outcomes, we performed Cox regression analyses comparing five-year OS in patients categorized as high or low for each neighbourhood. Having a higher density of the T cell dominant neighbourhood in the epithelium was associated with a decreased risk of death (HR: 0.41, 95% CI: 0.19-0.91, p<0.05). A higher

409 proportion of the T cell dominant neighbourhood within the peritumoural region was associated with

410 a decreased risk of death (HR: 0.45, 95% CI: 0.24-0.82, p<0.05) **(Figure 5E)**. These associations were

411 retained after multivariate Cox regression analysis **(Supplementary Table 3)**. Neither the

412 disorganized nor the macrophage dominant neighbourhoods were associated with OS. We conclude

413 that the spatial co-localization of T cells and B cells proximal to the tumour is prognostically

414 beneficial.

Discussion

PDAC tumours have a characteristically dense and desmoplastic stroma. The relative lack of anti-tumour immune cells and highly immunosuppressive features are well-recognized.[4,5,40] These observations have contributed to the prevailing view that PDAC may not be a suitable candidate for immunotherapy. However, recent studies reveal pockets of immune cell localization in PDAC,[7] suggesting that, at least in some regions, PDAC tumours may remain immunologically susceptible. We profiled the immune landscape of 73 patients with PDAC, designing custom algorithms to assess the tumours' unique ductal architecture. We found CD3+CD8- T cells to be associated with improved five-year OS, particularly when they localize to the tumour-stroma interface and when they coincide with CD3+CD8+ T cells in the tumour epithelium. T and B cell co-infiltration and co-localization were associated with the longest OS, supporting our conclusion that productive antitumour immunity results from the recruitment of cooperative immune cell types. This organization is consistent with that of the "T cell dominant" neighbourhood, where it would be expected that cytotoxic T cell immunity and antibody production could occur. This implies a susceptibility of PDAC to immune-mediated mechanisms and sets type I immunity as a goalpost for its future immunotherapy.

Immune profiling using IHC, single-cell mass cytometry, and flow cytometry has demonstrated that the extent and composition of T cell infiltration varies across patients with PDAC.[37,38,41–43] Transcriptomic analyses identified distinct immunologic subtypes in PDAC, including those that are immune-rich, immunosuppressive, immune-exhausted, or immune-depleted, reflecting both the extent and functional state of immune infiltration.[6–10,38] While transcriptomic subtypes reflect functional immune states, they do not fully capture the spatial heterogeneity observed within individual tumours. Recent studies demonstrate that tumours are not universally comprised of a single cell type or subregion.[7,44] This regional variation, "sub-TMEs", might reflect PDAC's continued growth and diversification,[45,46] and possibly a co-evolution with immunity and

immune escape. We similarly observe a range of immune cell densities between patients, with

CD3+CD8– T cells (likely CD4+ T cells), CD3+CD8+ T cells, and CD16a+ M2-like macrophages

representing the dominant phenotypes in both the epithelial and stromal compartments. This is

consistent with previous studies demonstrating that T cells are often the most abundant immune

population in the PDAC stroma, even exceeding myeloid cells.[38,41,47] With spatial assessments, we

note that B cells are also included in these neighbourhoods, so the T cell populations are likely

harbingers of more complex local immunity.

Higher densities of CD3+CD8– T cells in the stroma and T cell dominant neighbourhoods

were associated with lengthened five-year OS. Due to limitations in panel size, we could not stain for

CD4 directly, but infer these to be the CD3+CD4+ helper T cell subset. Likewise, an assessment of

the features of CD4+ subsets is beyond the scope of our panel, but the co-localization of CD3+CD8-

cells with B cells, M1 macrophages and CD3+CD8+ cells suggests their contribution to a type I

immune response (likely associated with the Th1 helper cell subset). Since these cells associate with

a survival benefit, we expect that they represent CD3+CD8–CD4+Foxp3– effector cells, which are

known to correlate with improved survival in PDAC.[37] CD4+ T helper cells promote anti-tumour

immunity by orchestrating dendritic cell activation and licensing, facilitating CD8+ T cell recruitment,

and supporting B cell maturation.[25] Helper T cell localization near the tumour border may facilitate

direct tumour cell killing through the release of cytotoxic cytokines (e.g. interferon-γ and tumour

necrosis factor-α) or engagement of death receptors including TRAIL and FasL.[25,48,49] Since these

functions can occur even at a distance, our findings of benefit to OS of CD3+CD8– T cells in both the

stroma and at the peritumoural regions still support a conclusion that these cells function as helpers.

The prognostic significance of stromal CD3+CD8– T cells was further enhanced when

CD3+CD8+ T cells were also present within the epithelium. Indeed, CD3+CD8+ T cells rarely infiltrate

in the absence of CD3+CD8– T cells, underscoring that these helper populations may facilitate the

recruitment or maintenance of the CD8+ populations in PDAC. CD3+CD8– T cells, CD3+CD8+ T cells,

and B cells co-infiltrated and co-localized, comprising the primary cell types in the T cell-dominated

neighbourhood. This spatial arrangement could reflect tertiary lymphoid structure (TLS)-like

formations: organized groupings of immune cells that are associated with improved overall survival

in PDAC[50–52]. TLSs support antigen presentation and adaptive immune activation; within them,

interactions between B cells, CD4+ T cells, and CD8+ T cells – such as antigen presentation, co-

stimulation, and cytokine-mediated signalling – promote coordinated immune responses.[18]

Although we did not have the necessary markers to definitively classify our T cell dominant

neighbourhoods as TLSs, the composition of these two types of neighbourhoods is aligned, and their

positioning at the tumour and peritumoural regions in patients with longer OS supports a productive

anti-cancer immunity.

In addition to the T cell dominant neighbourhood, we defined two others: macrophage-

dominant and disorganized. These may reflect immune subtypes previously described in PDAC. For

example, the macrophage dominant neighbourhood, enriched for CD16a+ M2-like macrophages and

exhibiting minimal T and B cell presence, may reflect an immunosuppressive environment consistent

with previously defined "basal-like", "squamous", or perhaps even "immune escape".[6,53,54] The T cell

dominant neighbourhood could reflect the previously defined "immune rich", "reactive", or

"adaptive/T cell dominant" regions.[6–8] Finally, the disorganized environment might reflect the

"deserted" or "immune-exclusion/tumour dominant" tumour regions.[6,8]

PDAC has a distinctive histology in which tumour cells originate in the ducts and often spread

as small, irregular clusters that are often interspersed within dense stroma.[19,20] Existing approaches

for spatial assessments were insufficient to capture this architecture, and methodological choices

can influence interpretation. In our study, we first identified tumour clusters, then defined 30-μm

borders around these clusters to capture both immune-immune and immune-tumour interactions

occurring in their vicinity. This approach was designed to capture the histology of PDAC and improve

biological relevance by reflecting the context in which immune activity at the tumour-stroma

interface may be as relevant as direct tumour contact.[55,56] Other studies using different spatial

definitions (e.g. measuring immune cell proximity within 20-μm of each tumour cells) have reported

associations between CD8+ T cells in direct contact with tumour cells and patient outcomes.[37] This

approach provides insight into direct tumour-immune interactions, but may not capture the broader

immune context, including activity at the tumour-stroma interface. This may explain why CD4+ T cell

proximity was not similarly associated with survival in those studies, despite their overall findings

supporting the prognostic relevance of T cell infiltration.[37] Our analysis, which used a different

spatial framework, may reflect complementary aspects of PDAC histology and immune dynamics.

Most patients with PDAC are diagnosed at advanced stages, whereas our cohort consisted

only of patients who underwent surgical resection (stage I-IIIa). Our findings thus reflect earlier-stage

disease and may not fully capture the TME of metastatic PDAC. It is possible that patients with

metastatic disease harbour a distinct TME.[45] While we did not observe an association between

tumour stage and immune contexture, it remains possible that tumours evolve toward becoming

disorganized or immunologically-cold as they progress to advanced stages. Although functional data

were beyond the scope of this work, our findings support future investigations and possible

interventions to maximize the activity of the TLS-like/T cell dominant neighbourhoods in PDAC.

Acknowledgements

We thank the patients who generously donated tissue and clinical information for this study, as well as the Nova Scotia Health Biobank for their contributions to sample and data collection. We are grateful to Craig's Cause Pancreatic Cancer Society for their support. Dalhousie University and the Boudreau laboratory are situated in Mi'kmi'ki, the traditional and unceded territory of the Mi'kmaq. This work was supported by the Canadian Cancer Society's Innovation (#705275) and JD Irving Atlantic Canada (#707195) grants to JEB. Clinical database creation was supported by a Nova Scotia Health Operating Grant and a Queen Elizabeth II Health Science Centre Foundation private donation research grant. RJA and JPM are trainees in the Cancer Research Training Program of the Beatrice Hunter Cancer Research Institute. Funds for RA and JPM are provided by GIVETOLIVE, by the Kilpatrick Trust through the Dalhousie Faculty of Medicine 2023 Graduate Studentship program, and by the Terry Fox MOHCCN Health Informatics and Data Scientist Awards. Funds for RA's work is supported by the Rick Salsman Pancreatic Cancer Studentship Fund through the Dalhousie Faculty of Medicine 2025 Graduate Studentship program.

References

1. Halbrook CJ, Lyssiotis CA, Pasca Di Magliano M, Maitra A. Pancreatic cancer: Advances and challenges. *Cell*. 2023;186(8):1729-1754. doi:10.1016/j.cell.2023.02.014

2. Lu J, Jiang G. The journey of CAR-T therapy in hematological malignancies. *Mol Cancer*. 2022;21(1):194. doi:10.1186/s12943-022-01663-0

3. Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. *The Lancet*. 2021;398(10304):1002-1014. doi:10.1016/S0140-6736(21)01206-X

4. Ju Y, Xu D, Liao M miao, et al. Barriers and opportunities in pancreatic cancer immunotherapy. *npj Precis Onc*. 2024;8(1):199. doi:10.1038/s41698-024-00681-z

5. Hartupee C, Nagalo BM, Chabu CY, et al. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. *Front Immunol*. 2024;15. doi:10.3389/fimmu.2024.1287459

6. Grünwald BT, Devisme A, Andrieux G, et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. *Cell*. 2021;184(22):5577-5592.e18. doi:10.1016/j.cell.2021.09.022

7. Wartenberg M, Cibin S, Zlobec I, et al. Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance. *Clinical Cancer Research*. 2018;24(18):4444-4454. doi:10.1158/1078-0432.CCR-17-3401

8. de Santiago I, Yau C, Heij L, et al. Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes. *Int J Cancer*. 2019;145(4):1125-1137. doi:10.1002/ijc.32186

9. Li R, He Y, Zhang H, et al. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy. *Front Immunol*. 2021;12. doi:10.3389/fimmu.2021.690056

10. Chen Y, Chen D, Wang Q, et al. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification. *Front Immunol*. 2022;12. doi:10.3389/fimmu.2021.719105

11. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer | Nature. Accessed October 14, 2025. https://www.nature.com/articles/s41586-023-06063-y

12. Sethna Z, Guasp P, Reiche C, et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. *Nature*. 2025;639(8056):1042-1051. doi:10.1038/s41586-024-08508-4

13.   Li X, Gruosso T, Zuo D, et al. Infiltration of CD8+ T cells into tumor cell clusters in
triple-negative breast cancer. *Proceedings of the National Academy of Sciences*.
2019;116(9):3678-3687. doi:10.1073/pnas.1817652116

14.   Bull JA, Macklin PS, Quaiser T, et al. Combining multiple spatial statistics enhances
the description of immune cell localisation within tumours. *Sci Rep*. 2020;10(1):18624.
doi:10.1038/s41598-020-75180-9

15.   Schürch CM, Bhate SS, Barlow GL, et al. Coordinated Cellular Neighborhoods
Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. *Cell*.
2020;182(5):1341-1359.e19. doi:10.1016/j.cell.2020.07.005

16.   Nersesian S, Arseneau RJ, Mejia JP, et al. Improved overall survival in patients with
high-grade serous ovarian cancer is associated with CD16a+ immunologic
neighborhoods containing NK cells, T cells and macrophages. *Front Immunol*. 2024;14.
doi:10.3389/fimmu.2023.1307873

17.   Xu H, Cha YJ, Clemenceau JR, et al. Spatial analysis of tumor-infiltrating
lymphocytes in histological sections using deep learning techniques predicts survival in
colorectal carcinoma. *The Journal of Pathology: Clinical Research*. 2022;8(4):327-339.
doi:10.1002/cjp2.273

18.   Liu C, Cao J. The pivotal role of tertiary lymphoid structures in the tumor immune
microenvironment. *Front Oncol*. 2025;15. doi:10.3389/fonc.2025.1616904

19.   Kearney JF, Adsay V, Yeh JJ. Pathology and Molecular Characteristics of Pancreatic
Cancer. *Surg Oncol Clin N Am*. 2021;30(4):609-619. doi:10.1016/j.soc.2021.06.003

20.   Klöppel G, Adsay NV. Chronic Pancreatitis and the Differential Diagnosis Versus
Pancreatic Cancer. *Arch Pathol Lab Med*. 2009;133(3):382-387. doi:10.5858/133.3.382

21.   A Grammar of Data Manipulation. Accessed October 10, 2025.
https://dplyr.tidyverse.org/

22.   Type, Density, and Location of Immune Cells Within Human Colorectal Tumors
Predict Clinical Outcome | Science. Accessed October 10, 2025. https://www-science-
org.ezproxy.library.dal.ca/doi/10.1126/science.1129139

23.   Galon J, Fridman WH, Pagès F. The Adaptive Immunologic Microenvironment in
Colorectal Cancer: A Novel Perspective. *Cancer Res*. 2007;67(5):1883-1886.
doi:10.1158/0008-5472.CAN-06-4806

24.   Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8+ T cells in cancer and
cancer immunotherapy. *Br J Cancer*. 2021;124(2):359-367. doi:10.1038/s41416-020-
01048-4

590 25. Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W. CD4+ T cell help in cancer
591   immunology and immunotherapy. *Nat Rev Immunol*. 2018;18(10):635-647.
592   doi:10.1038/s41577-018-0044-0

593 26. Wolf S, Anastasopoulou V, Drousch K, et al. 403 A four-cell type interaction between
594   CD4+ T cells, CD8+ T cells, stromal and cancer cells as a potential mechanism for
595   cancer eradication when one CD4TCR is combined with one CD8TCR. *J Immunother*
596   *Cancer*. 2024;12(Suppl 2). doi:10.1136/jitc-2024-SITC2024.0403

597 27. Ouyang P, Zhang J, He X, Yang C, Zeng D, Xu D. Infiltration characteristics and
598   regulatory mechanisms of CD8+ T lymphocytes in solid tumors: spatial distribution,
599   biological functions, and interactions with the immune microenvironment. *Front*
600   *Immunol*. 2025;16. doi:10.3389/fimmu.2025.1661545

601 28. McKinney W. Data Structures for Statistical Computing in Python. In: 2010:56-61.
602   doi:10.25080/Majora-92bf1922-00a

603 29. Harris CR, Millman KJ, van der Walt SJ, et al. Array programming with NumPy.
604   *Nature*. 2020;585(7825):357-362. doi:10.1038/s41586-020-2649-2

605 30. Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: Machine Learning in
606   Python. *J Mach Learn Res*. 2011;12(null):2825-2830.

607 31. davies_bouldin_score. scikit-learn. Accessed October 10, 2025. https://scikit-
608   learn/stable/modules/generated/sklearn.metrics.davies_bouldin_score.html

609 32. Hunter JD. Matplotlib: A 2D Graphics Environment. *Computing in Science &*
610   *Engineering*. 2007;9(3):90-95. doi:10.1109/MCSE.2007.55

611 33. Journal of Open Source Software: seaborn: statistical data visualization. Accessed
612   July 31, 2025. https://joss.theoj.org/papers/10.21105/joss.03021

613 34. Ester M, Kriegel HP, Xu X. A Density-Based Algorithm for Discovering Clusters in
614   Large Spatial Databases with Noise.

615 35. Virtanen P, Gommers R, Oliphant TE, et al. SciPy 1.0: fundamental algorithms for
616   scientific computing in Python. *Nat Methods*. 2020;17(3):261-272. doi:10.1038/s41592-
617   019-0686-2

618 36. Sivakumar S, Jainarayanan A, Arbe-Barnes E, et al. Distinct immune cell infiltration
619   patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell
620   selection and immunosuppressive mechanisms. *Nat Commun*. 2025;16(1):1397.
621   doi:10.1038/s41467-024-55424-2

37. Carstens JL, Correa de Sampaio P, Yang D, et al. Spatial computation of intratumoral
T cells correlates with survival of patients with pancreatic cancer. *Nat Commun*.
2017;8(1):15095. doi:10.1038/ncomms15095

38. Wang H, Chen L, Qi L, et al. A Single-Cell Atlas of Tumor-Infiltrating Immune Cells in
Pancreatic Ductal Adenocarcinoma. *Molecular & Cellular Proteomics*.
2022;21(8):100258. doi:10.1016/j.mcpro.2022.100258

39. Yu M, Guan R, Hong W, et al. Prognostic value of tumor-associated macrophages in
pancreatic cancer: a meta-analysis. *Cancer Manag Res*. 2019;11:4041-4058.
doi:10.2147/CMAR.S196951

40. Guo S, Wang Z. Unveiling the immunosuppressive landscape of pancreatic ductal
adenocarcinoma: implications for innovative immunotherapy strategies. *Front Oncol*.
2024;14:1349308. doi:10.3389/fonc.2024.1349308

41. Blando J, Sharma A, Higa MG, et al. Comparison of immune infiltrates in melanoma
and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.
Proceedings of the National Academy of Sciences. 2019;116(5):1692-1697.
doi:10.1073/pnas.1811067116

42. Stromnes IM, Hulbert A, Pierce RH, Greenberg PD, Hingorani SR. T-cell Localization,
Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. *Cancer
Immunology Research*. 2017;5(11):978-991. doi:10.1158/2326-6066.CIR-16-0322

43. Steele NG, Carpenter ES, Kemp SB, et al. Multimodal mapping of the tumor and
peripheral blood immune landscape in human pancreatic cancer. *Nat Cancer*.
2020;1(11):1097-1112. doi:10.1038/s43018-020-00121-4

44. Hilmi M, Delecourt F, Raffenne J, et al. Redefining phenotypic intratumor
heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach. *J Pathol*.
2025;265(4):448-461. doi:10.1002/path.6398

45. Li Y, Ding Z, Cheng T, et al. Single-cell transcriptomics analysis reveals dynamic
changes and prognostic signature in tumor microenvironment of PDAC. *Scientific
Reports*. 2025;15(1):4025. doi:10.1038/s41598-025-86950-8

46. Mullen KM, Hong J, Attiyeh MA, et al. The Evolutionary Forest of Pancreatic Cancer.
Cancer Discov. 2025;15(2):329-345. doi:10.1158/2159-8290.CD-23-1541

47. Shibuya KC, Goel VK, Xiong W, et al. Pancreatic Ductal Adenocarcinoma Contains
an Effector and Regulatory Immune Cell Infiltrate that Is Altered by Multimodal
Neoadjuvant Treatment. *PLOS ONE*. 2014;9(5):e96565.
doi:10.1371/journal.pone.0096565

48.   Tateyama M, Oyaizu N, McCloskey TW, Than S, Pahwa S. CD4 T lymphocytes are
primed to express Fas ligand by CD4 cross-linking and to contribute to CD8 T-cell
apoptosis via Fas/FasL death signaling pathway: Presented in part at the 12th World
AIDS Conference, Geneva, Switzerland, 1998. *Blood*. 2000;96(1):195-202.
doi:10.1182/blood.V96.1.195

49.   Thomas WD, Zhang XD, Franco AV, Nguyen T, Hersey P. TNF-Related Apoptosis-
Inducing Ligand-Induced Apoptosis of Melanoma Is Associated with Changes in
Mitochondrial Membrane Potential and Perinuclear Clustering of Mitochondria1. *The*
Journal of Immunology. 2000;165(10):5612-5620. doi:10.4049/jimmunol.165.10.5612

50.   Zou X, Lin X, Cheng H, et al. Characterization of intratumoral tertiary lymphoid
structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic
significance. *J Immunother Cancer*. 2023;11(6):e006698. doi:10.1136/jitc-2023-006698

51.   Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T, Shimada K. Intratumoral
tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer.
Br J Cancer. 2015;112(11):1782-1790. doi:10.1038/bjc.2015.145

52.   Lehmann J, Thelen M, Kreer C, et al. Tertiary Lymphoid Structures in Pancreatic
Cancer are Structurally Homologous, Share Gene Expression Patterns and B-cell Clones
with Secondary Lymphoid Organs, but Show Increased T-cell Activation. *Cancer*
Immunology Research. 2025;13(3):323-336. doi:10.1158/2326-6066.CIR-24-0299

53.   Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes
of pancreatic cancer. *Nature*. 2016;531(7592):47-52. doi:10.1038/nature16965

54.   Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct
tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. *Nat Genet*.
2015;47(10):1168-1178. doi:10.1038/ng.3398

55.   Feng Z, Bethmann D, Kappler M, et al. Multiparametric immune profiling in HPV– oral
squamous cell cancer. *JCI Insight*. 2(14):e93652. doi:10.1172/jci.insight.93652

56.   Oyler-Yaniv A, Oyler-Yaniv J, Whitlock BM, et al. A Tunable Diffusion-Consumption
Mechanism of Cytokine Propagation Enables Plasticity in Cell-to-Cell Communication in
the Immune System. *Immunity*. 2017;46(4):609-620. doi:10.1016/j.immuni.2017.03.011

Data availability

The data generated and code used in this study are available upon request from the

corresponding author.